3 Australian Penny Stocks Backed By Strong Financial Health

Penny stocks often get attention for the wrong reasons, yet the Financially Fit Penny Stocks screener focuses on something much simpler. It highlights companies trading below 5 that also show solid financial health. In a world where central banks are weighing inflation against growth, energy prices influence rate expectations, and economic signals vary by region, that kind of discipline matters. This approach provides exposure to earlier stage opportunities without relying solely on hope. This article walks through 3 stocks from the screener and shows how they fit this financial health driven approach.

DroneShield (ASX:DRO)

Overview: DroneShield is a Sydney based defence technology company that builds hardware and software to detect and disable hostile drones for customers including militaries, security agencies and critical infrastructure operators around the world.

Operations: DroneShield currently generates about A$216.8 million in revenue, all from its Aerospace & Defense activities across the USA and the rest of the world.

Market Cap: A$1.6b

DroneShield operates in a segment of defence spending that is receiving continued attention, as militaries, governments and major event organisers look for reliable ways to detect and counter drones. The company has moved beyond one-off wins and is building repeat institutional relationships, supported by contracts such as the recent A$23.2 million European defence deals and deployments tied to major events like the FIFA World Cup 2026. Current valuation is high relative to estimated cash flows and ROE remains low. With an ASIC investigation ongoing and funding that relies on external borrowing, investors may wish to focus on how consistently DroneShield converts its order book into profitable, longer term contracts.

DroneShield’s accelerating contract wins raise a clear question: Is the current price already baking in the story, or is the real inflection still ahead? Get the full picture in the analysis report for DroneShield

Sigma Healthcare (ASX:SIG)

Overview: Sigma Healthcare is a long established Australian pharmacy group that supplies medicines and health products to community pharmacies, franchises retail brands like Chemist Warehouse, Amcal and Discount Drug Stores, and provides logistics and support services to pharmaceutical manufacturers, both in store and online.

Operations: Sigma Healthcare generates about A$9.5b in revenue, largely from its Healthcare operations, with A$9.2b from Australia and A$389.8m from international markets.

Market Cap: A$34.0b

Investors looking at Sigma Healthcare can see a large scale distributor and franchisor with earnings and revenue growth forecasts that sit ahead of the wider Australian market, yet the stock trades only slightly below estimated fair value. The story is not one way, though. Net margins have narrowed from 11.5% to 6.3%, the P/E is high relative to peers and all funding relies on external borrowing, which raises questions about resilience if conditions tighten. A relatively new and less independent board adds another layer for you to weigh. The interest comes from whether this mix of solid growth and execution risk is being priced correctly, especially after Sigma stepped back from the Boots UK talks to focus on its core opportunities.

Sigma Healthcare appears to be a large, steady operator; however, its combination of a high P/E ratio, thinner margins and reliance on external borrowing suggests a more complex story than the headline numbers indicate. See how the market is weighing that balance in the 3 key rewards and 1 important warning sign

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech that develops regenerative cell therapies using mesenchymal lineage cells to treat severe inflammatory, cardiovascular and pain conditions, including pediatric and adult graft versus host disease, chronic low back pain and chronic heart failure.

Operations: Mesoblast generates about US$65.4 million in revenue from developing its cell technology platform for commercialization.

Market Cap: A$2.7b

Mesoblast stands out in the penny stock space because it already has an FDA approved cell therapy, Ryoncil, together with more than 1,100 patents, commercial scale manufacturing and growing product revenue in a sector where many peers are still pre commercial. The stock trades below some fair value estimates, but the company is still loss making and relies on higher risk external borrowing to fund an extensive pipeline. Much of the long term story hinges on label expansions, new indications and regulatory decisions in large markets like chronic low back pain and heart failure, so a key consideration is how much of that potential is already reflected in the share price.

Mesoblast already has an FDA approved therapy and large patent estate, yet the stock still trades as if the story is unfinished. See how the market is framing that gap in the full narrative for Mesoblast

The three stocks here are just a starting point, and the full Financially Fit Penny Stocks screener surfaces 404 more companies that pair low share prices with balance sheets and cash flows that help support their stories. Use Simply Wall St to identify, analyze and filter for the exact catalysts and narratives that matter most to you, so you can focus on the opportunities you find most compelling in this corner of the market.

Take Control of Your Investment Journey

If Mesoblast or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What You Might Be Missing

Fresh ideas do not stay under the radar for long. Stocks can move from quiet to breakout while you wait. Check these curated lists before momentum starts flying and consider acting promptly.

• Spot companies with strong cash generation and balance sheets before they gain wider attention by scanning this curated group of 7 high quality undervalued stocks.
• Tap into structural shifts in power and grid technology by reviewing a focused set of infrastructure businesses in the 35 power grid technology and infrastructure stocks.
• Focus on consistent cash payers with higher yields by working through a hand picked group of 4 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com